Rekrutteringsfirma

Principal/ Senior Analytical Development Scientist

Denne stilling er desværre ikke længere ledig.
Se alle ledige stillinger

Gå tilbage til ledige stillinger

Principal/ Senior Analytical Development Scientist

Pioneer the development of a new class of drugs halting disease progression and restoring function.

https://uhc.dk/wp-content/uploads/2023/10/Video-teaser-Draft-V1.mp4

As Principal/ Senior Analytical Development Scientist at Vicore Pharma, you will be the project lead for analytical method development for Vicore’s lead candidate drugs.

Your main responsibilities include:

  • Developing, validating, and implementing product-specific analytical methods
  • Leading projects with analytical teams
  • Directing the outlining of agreements for analytical tasks
  • Managing execution of the analytical control strategies and the regulatory documentation for the CMC part of INDs/IMPDs, and eventually for the registration file

Your qualifications include at least five to seven years of experience in the pharmaceutical and/or biotechnology industry, where you have been actively working with CMC and analytical development, including small molecules. Additionally, you have contributed to regulatory documents and submissions, as well as involved in the clinical development of investigational new drugs.

You are a person who has a positive attitude and are open to collaborating and communicating with colleagues across different departments. Furthermore, you enjoy being challenged and can work with multiple tasks. As a principal /senior scientist, you find it natural to drive the fundamentals of the process of developing new medicine.

Vicore Pharma is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs, angiotensin II type 2 receptor agonists (ATRAG) for severe diseases.
Vicore has a unique expertise within the ATRAG biology and a holistic approach in diseases where the angiotensin II type 2 receptor has a central role in stopping and reversing disease pathology. Vicore’s pipeline has several assets with long patent life for a variety of diseases. Our lead indication is idiopathic pulmonary fibrosis, and our most advanced candidate drug, C21, is currently completing a phase 2a clinical trial and preparing for the next phase.

Vicore is a lean and agile organization with highly experienced professionals who cover the entire spectrum from early asset development through to commercialization and patient access. Vicore’s success hinges on the capacity to attract and retain talented individuals who are deeply committed, adaptable to change, and thrive in a dynamic environment with ambitious goals. All employees are equally important to turn the Vicore ambition into reality. Through valuing trust, integrity, and an open, friendly, and informal atmosphere, you can expect great opportunities for impact and growth.

Travelling: Approx. 10-20 days per year.

Domicile: Commuting distance from the Vicore office in Hørsholm, Copenhagen.

For more details about the job or the company, please contact Director Life Science Gert Andersen, Unique Human Capital, on M: +45 42 95 08 83, [email protected].
All applications must be in English and are treated confidentially.


Information og data

Denne ledige stilling har jobtypen "Forsker", og befinder sig i kategorien "Sundhed og forskning".

Jobbet er oprettet på vores service den 19.10.2023, men kan have været deaktiveret og genaktiveret igen.

Dagligt opdateret: Dette job opdateres dagligt ud fra jobudbyderens hjemmeside via vores søgemaskineteknologi og er aktivt lige nu.
  • Forsker

Statistik over udbudte jobs som forskere

Herunder ser du udviklingen i udbudte forsker over tid. Bemærk at jobs der ikke har en bestemt geografi ikke er medtaget i tabellen. I den første kolonne ser du datoen. I den næste kolonne ser du det samlede antal forskere.

Se flere statistikker her:
Statistik over udbudte forskere over tid

Dato Alle jobs som forskere
25. januar 2025 370
24. januar 2025 372
23. januar 2025 372
22. januar 2025 353
21. januar 2025 359
20. januar 2025 366
19. januar 2025 368
18. januar 2025 364
17. januar 2025 352
16. januar 2025 349
15. januar 2025 378
14. januar 2025 359
13. januar 2025 337
12. januar 2025 355
11. januar 2025 365
10. januar 2025 359
9. januar 2025 342
8. januar 2025 327
7. januar 2025 320
6. januar 2025 330
5. januar 2025 347
4. januar 2025 351
3. januar 2025 361
2. januar 2025 366
1. januar 2025 367
31. december 2024 374
30. december 2024 381
29. december 2024 380
28. december 2024 375
27. december 2024 382
26. december 2024 389